Clinical Trial

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in certain other studies for CD or UC (called a parent study) may be able to join this study. The goals of this study are to learn about the safety of tulisokibart over time in people with CD or UC, and if people tolerate it.
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2024-10-18; most recent amendment 2026-05-15.
Status change: Not Yet Recruiting → Recruiting 2024-12-02
Trial Details
NCT Number NCT06651281
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Crohn Disease, Colitis, Ulcerative
Enrollment 1,380 participants
Start Date 2024-11-25
Primary Completion 2037-12-17 (estimated)
Study Completion 2037-12-17 (estimated)
Updated on ClinicalTrials.gov 2026-05-19